Trametinib - Novartis

Drug Profile

Trametinib - Novartis

Alternative Names: 1120212; GSK-1120212; GSK-1120212B; JTP-74057; Mecinist; Mekinist; Mekinisuto; TMT 212; Trametinib dimethyl sulfoxide; Trametinib DMSO

Latest Information Update: 25 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Japan Tobacco
  • Developer Amgen; Dana-Farber Cancer Institute; GlaxoSmithKline; Japan Tobacco; M. D. Anderson Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); Novartis; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma; Non-small cell lung cancer
  • Registered Thyroid cancer
  • Phase II Acute myeloid leukaemia; Biliary cancer; Brain metastases; Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Glioma; Multiple myeloma; Myeloid leukaemia; Pancreatic cancer; Uveal melanoma
  • Phase I/II Solid tumours
  • No development reported Leukaemia; Lymphoma; Mesothelioma
  • Discontinued Inflammation

Most Recent Events

  • 20 Sep 2018 Novartis and Massachusetts General Hospital plan a phase II trial for Colorectal cancer (Combination therapy, Metastatic disease) in USA in September 2018 (NCT03668431)
  • 17 Sep 2018 Launched for Malignant melanoma (Combination therapy, Adjuvant therapy) in United Kingdom (PO)
  • 17 Sep 2018 National Institute for Health and Care Excellence recommends the approval of dabrafenib and trametinib combination for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following surgery
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top